PRESS RELEASE published on 11/06/2024 at 22:30, 1 year 10 months ago DBV Technologies Reports Third Quarter 2024 Financial Results DBV Technologies reports Q3 2024 financial results, with $46.4 million cash balance. Approves quarterly financial statements. Faces challenges in securing future financing Financial Results Financing Clinical Trials Cash Balance DBV Technologies
BRIEF published on 10/31/2024 at 09:05, 1 year 10 months ago Braidwell LP Crosses Thresholds in DBV Technologies Warrants Actions DBV Technologies Participation Threshold Braidwell LP
BRIEF published on 10/22/2024 at 22:50, 1 year 10 months ago DBV's Viaskin Peanut Patch Secures Regulatory Progress in US and EU FDA Approval DBV Technologies Viaskin Peanut Regulatory Update EMA Guidance
PRESS RELEASE published on 10/22/2024 at 22:45, 1 year 10 months ago DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe DBV Technologies announces positive regulatory updates for Viaskin Peanut Patch in the United States and Europe, aiming for Accelerated Approval for toddlers 1-3 years old Accelerated Approval Regulatory Updates DBV Technologies Viaskin Peanut Patch Toddlers
BRIEF published on 10/18/2024 at 22:35, 1 year 10 months ago DBV Technologies to Engage in ACAAI 2024 Congress DBV Technologies Allergy Treatment Peanut Allergy Viaskin Peanut Patch ACAAI 2024
PRESS RELEASE published on 10/18/2024 at 22:30, 1 year 10 months ago DBV Technologies to Participate in Upcoming ACAAI 2024 Congress DBV Technologies to participate in ACAAI 2024 Congress, presenting on optimal peanut allergy treatment and sponsoring FIT Bowl. Viaskin Peanut patch for food allergies highlighted DBV Technologies Food Allergies Viaskin Peanut Patch ACAAI 2024 Congress Peanut Allergy Treatment
BRIEF published on 10/14/2024 at 22:35, 1 year 10 months ago DBV Technologies Share Capital Status as of September 30, 2024 Share Capital Voting Rights DBV Technologies Euronext Exchanges Listed Shares
BRIEF published on 09/23/2024 at 22:35, 1 year 11 months ago DBV Technologies Completes Screening of Subjects for Phase 3 VITESSE Clinical Trial Clinical Trial Phase 3 DBV Technologies Viaskin Peanut Peanut Allergy
PRESS RELEASE published on 09/23/2024 at 22:30, 1 year 11 months ago DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial DBV Technologies completes screening for VITESSE Phase 3 Clinical Trial evaluating Viaskin Peanut Patch in peanut allergic children ages 4-7. Topline results expected Q4 2025 Clinical Trial DBV Technologies Food Allergies VITESSE Phase 3 Viaskin Peanut Patch
BRIEF published on 09/04/2024 at 22:35, 2 years ago DBV Technologies to Participate in 26th Annual HC Wainwright Global Investment Conference DBV Technologies Viaskin Food Allergies HC Wainwright Lecture Epicutaneous Immunotherapy
Published on 09/12/2026 at 02:35, 1 day 17 hours ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 1 day 21 hours ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 21:25, 1 day 23 hours ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 2 days 3 hours ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 17:50, 1 day 2 hours ago New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 1 day 13 hours ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 1 day 22 hours ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 1 day 22 hours ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 2 days ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 07:00, 2 days 13 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/10/2026 at 19:30, 3 days 1 hour ago Availability of the 2026 Interim Financial Report
